Close

GW Pharma (GWPH): Epidiolex Approved...But Expected - Goldman Sachs

June 26, 2018 7:14 AM EDT
Get Alerts GWPH Hot Sheet
Price: $218.96 --0%

Rating Summary:
    13 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 9 | New: 10
Join SI Premium – FREE

Goldman Sachs analyst, Salveen Richter, reiterated his Buy rating on shares of GW Pharma (NASDAQ: GWPH) after the company received FDA approval for Epidiolex in patients two-years of age and older for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS).

The analyst stated "Approval was largely expected post the unanimous vote for approval at the FDA Adcom (April 19) as well as the compelling profile from three Ph3 clinical trials and one open-label extension study". In his investment thesis, he also points out "We view GWPH as an attractive M&A target (M&A rank of 2) given the company owns global rights to a first-in-class cannabinoid Epidiolex for the treatment of severe epilepsies with the potential for wide off-label use in non-orphan seizure
disorders".

No change to the price target of $188.

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $144.76 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Goldman Sachs, FDA